ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1424	National Cancer Institute	Html	en	Liver (Hepatocellular) Cancer Screening (PDQ®)–Health Professional Version	Expert-reviewed information summary about tests used to detect or screen for liver (hepatocellular) cancer.	positive predictive value 0.503935 Needle aspiration cytology 0.492344 10-year survival rates 0.485559 hepatitis B virus 0.608203 hepatitis G infection 0.516552 control group 0.576587 6-monthly AFP assays 0.575205 North America 0.429041 nonalcoholic steatohepatitis 0.42282 AFP screening 0.526835 usual-care group 0.429439 ethnic groups 0.421496 test result 0.419937 HCC 0.942449 screening group 0.63461 Age-standardized incidence rates 0.541219 hepatitis B infection 0.498394 glycogen storage disease 0.517803 porphyria cutanea tarda 0.523911 new cases 0.427232 patients experience pain 0.502381 Serum AFP 0.49956 fetal-specific glycoprotein antigen 0.51455 United States 0.614175	screening tests 0.450593 retrospective case-control study 0.516703 mortality rate ratio 0.509505 certain Aspergillus species 0.510442 widely used tumor 0.501438 cryptogenic cirrhosis 0.452869 earlier diagnosis 0.555097 right upper quadrant 0.485875 common cancer 0.432709 surface antigen–positive carriers 0.524371 diagnosis study designs. 0.509206 Chinese Americans 0.422068 high incidence 0.419907 distinct male preponderance 0.54002 risk factor 0.421115 HCC mortality 0.712636 mortality rate 0.512472 randomized controlled trial 0.492498 alcoholic cirrhosis 0.45216 chronic hepatitis 0.816099 germ cell tumors 0.509004 liver biopsy 0.576034 annual risk 0.42449 liver cancer 0.48682	CLICK HERE
1453	National Cancer Institute	Html	en	Esophageal Cancer Prevention (PDQ®)–Health Professional Version	Expert-reviewed information summary about factors that may influence the risk of developing esophageal cancer and about research aimed at the prevention of this disease.	population-based case-controlled study 0.456088 Incidence rates 0.385333 symptomatic gastroesophageal reflux 0.449595 Barrett epithelium 0.458468 control group 0.467545 population attributable risk 0.450158 abnormal intestinal-type epithelium 0.466177 upper gastrointestinal hemorrhage 0.4271 GERD symptoms 0.44816 dysplastic Barrett esophagus 0.622479 distal esophagus 0.516913 case-control studies 0.466408 characteristic endoscopic appearance 0.435919 racial/ethnic groups 0.387576 alcohol abuse 0.441548 sham ablation 0.397202 patients 0.529714 incidence rate 0.442768 relative risk 0.448332 long-standing GERD 0.393778 esophageal adenocarcinoma 0.436843 esophageal adenocarcinoma. 0.389793 Retrospective cohort studies 0.444668 radiofrequency ablation 0.397459	new cases 0.385134 population-based cohort study 0.450776 esophageal cancer 0.543708 United States 0.381547 neoplastic alteration 0.380441 squamous epithelium. 0.390253 Barrett esophagus 0.930056 disease progression 0.441468 low-grade dysplasia 0.40734 significantly increased risk 0.448898 recurrent reflux symptoms 0.445059 important epidemiological difference 0.443496 black men 0.381968 case-control study 0.397548 high-grade dysplasia group 0.469185 adenocarcinoma 0.464553 certain GERD symptoms 0.4422 risk factor 0.383382 randomized controlled trial 0.433019 treatment group 0.414938 stratified squamous epithelium 0.484787 ablation group 0.497322 risk 0.45334 columnar epithelium 0.407571	CLICK HERE
1505	National Cancer Institute	Html	en	Transitional Cell Cancer of the Renal Pelvis and Ureter Treatment (PDQ®)–Health Professional Version	Expert-reviewed information summary about the treatment of renal pelvis and ureter transitional cell cancer.	high response rates 0.570253 significant advantage 0.396071 segmental excision 0.901561 distal ureter 0.436419 lymph node dissection 0.603868 single-agent cisplatin 0.443409 transitional cell carcinoma 0.586392 renal pelvic tumors 0.538563 overall response rate 0.528335 pelvic transitional cell 0.448218 upper tract unit 0.412776 Flow cytometry analysis 0.411659 renal pelvic neoplasia 0.501661 ipsilateral ureter 0.431511 bladder cuff 0.478483 tumor grade 0.387333 ureter 0.507683 decreased renal function 0.469412 randomized trial 0.409787 advanced bladder cancer 0.608478 cooperative group trial 0.54025 M-VAC 0.376891 probable extensive involvement 0.400061 low-grade lesions 0.376767 incomplete excision 0.438555	transitional cell cancer 0.423006 occasional complete responses. 0.574974 median survival 0.546148 flexible ureteroscopic techniques 0.426625 low-grade tumors 0.414223 total excision 0.42951 unique structural aspects 0.436892 proximal disease 0.421433 tumor recurrence 0.752566 entire ureter 0.43284 regional lymph node 0.419107 upper tract tumors 0.459629 subepithelial connective tissue 0.406583 recurrent transitional cell 0.585792 combination chemotherapy 0.403167 highly selected patients 0.420394 original pelvic tumor 0.49757 lymph node involvement 0.412201 section histologic diagnosis 0.406599 periureteral orifice mucosa 0.421167 upper tract 0.553387 upper tract neoplasm 0.442928 renal pelvis 0.622775 transitional cell 0.664348	CLICK HERE
1668	National Cancer Institute	Html	en	Childhood Central Nervous System Atypical Teratoid/Rhabdoid Tumor Treatment (PDQ®)–Health Professional Version	Expert-reviewed information summary about the treatment of childhood atypical teratoid/rhabdoid tumors	sporadic atypical teratoid/rhabdoid 0.35389 Advanced Solid Tumors 0.266343 germline mutations 0.346295 Brain Tumor Registry 0.34992 PDQ cancer information 0.28675 childhood brain tumor 0.395256 highly malignant tumor 0.338658 children 0.248192 Teratoid/Rhabdoid Tumor Registry 0.377339 epithelial membrane antigen 0.26533 Tumors Treatment Overview 0.317468 teratoid rhabdoid tumor 0.482755 CNS embryonal tumor 0.333819 childhood atypical teratoid 0.359626 cancer information summary 0.273796 World Health Organization 0.305191 AT/RT 0.337582 renal rhabdoid tumor 0.427367 term rhabdoid tumor 0.444598 non-CNS tumors 0.241796 extrarenal rhabdoid malignancies. 0.28465 malignant rhabdoid tumor 0.405902 common solid tumor 0.361944 radiation therapy 0.251981 candidate tumor suppressor 0.315221	atypical teratoid/rhabdoid tumors 0.837543 Cribriform neuroepithelial tumor 0.311275 Rhabdoid cells 0.24146 CNS tumors 0.263956 posterior fossa 0.268656 PUBMED Abstract 0.244289 germline alterations 0.247965 tumor suppressor gene 0.428299 primitive neuroectodermal tumor 0.317136 Tumor location 0.308144 Primary brain tumors 0.317725 Pediatr Hematol Oncol 0.369559 nervous system tumors 0.313542 adolescent cancer survivors 0.310424 brain tumor 0.438808 Germline INI1 mutation 0.247063 atypical teratoid/rhabdoid tumor 0.959627 PDQ summary 0.241675 atypical teratoid tumor 0.422531 recurrent solid tumors 0.264311 Nervous System Atypical 0.266779 tumor diagnosis 0.312232 pediatric brain tumor 0.327372 Biegel JA 0.277305	CLICK HERE
1786	National Cancer Institute	Html	es	Linfedema (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos acerca del tratamiento del linfedema.	siguientes áreas 0.436931 causa hinchazón 0.778344 pequeña cantidad 0.464081 pequeños cortes 0.452311 siguientes abordajes 0.459419 PDQ Linfedema 0.618416 sección información 0.436578 largo plazo 0.580542 protector solar 0.453778 sección manejo 0.432902 National Cancer Institute 0.432858 ropa flojos 0.450402 siguientes riesgos 0.424859	Instituto Nacional 0.463187 siguientes problemas 0.490486 linfedema atrapa 0.967072 Physician Data Query 0.535003 Estados Unidos 0.442188 estadio iii 0.728645 siguientes medidas 0.469803 linfa circula 0.531655 linfedema.ampliar anatomía 0.480452 siguientes pruebas 0.475048 uñas ayuda 0.454713 baja potencia 0.433231	CLICK HERE
2036	National Cancer Institute	Html	es	Tratamiento de las neoplasias mieloproliferativas crónicas (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos acerca del tratamiento de las neoplasias mieloproliferativas crónicas.	siguientes procedimientos 0.417826 células madre 0.649424 siguientes aspectos 0.405563 leucemia aguda 0.417682 cuerpo.ampliar trasplante 0.403016 hueso compacto 0.418199 genes mpl 0.404719 enlace drugs approved 0.416336 célula madre mieloide 0.431519 genes jak2 0.404899 Sudores nocturnos 0.404299 células anormales.ampliar aspiración 0.420044 National Cancer Institute 0.401966 siguientes riesgos 0.401801 Instituto Nacional 0.403647 célula madre linfoide 0.432844	PDQ Tratamiento 0.431983 leucemia mielógena 0.471893 Drugs Approved 0.417258 Physician Data Query 0.407937 llamada mielofibrosis 0.427648 serios problemas 0.403469 Myeloproliferative Neoplasms 0.417257 siguientes sustancias 0.403598 policitemia vera 0.696975 leucemia mieloide aguda 0.414565 gen jak2 0.405058 célula madre 0.501376 células sanguíneas maduras 0.468721 neoplasias mieloproliferativas 0.925417 siguientes pruebas 0.407534	CLICK HERE
3415	National Cancer Institute	Html	en	NCI and the Precision Medicine Initiative®	NCI's activities related to precision medicine focuses on new and expanded precision medicine clinical trials; mechanisms to overcome drug resistance to cancer treatments; and developing a shared digital repository of precision medicine trials data.	Cancer Master Protocol 0.614776 precision oncology 0.587102 clinical response data 0.576467 Human Cancer Models 0.613841 medicine clinical trials 0.84157 Enrichment Marker Identification 0.553367 pilot extramural drug 0.559375 genetically targeted therapies 0.561429 cancer therapy 0.603283 NCI Patient-Derived Models 0.701176 cancer cell line 0.595282 immunotherapy clinical trials 0.61741 additional data sets 0.566068 patients 0.627055 cancer patients 0.582113 Genomic Data Commons 0.5718 Adjuvant Lung Cancer 0.615432 NCI 0.886136 human cancer 0.6328 precision medicine 0.986526 NCI early-phase trials 0.710312 relevant preclinical data 0.574529 human cancer cell 0.605887 drug resistance 0.561963 detailed sequencing analyses 0.555402	new laboratory models 0.716729 precision medicine trials 0.644469 Molecular Profiling-Based Assignment 0.559435 cancer research community 0.606845 radiation therapy studies 0.56117 Pediatric MATCH 0.560552 molecularly characterized samples 0.553516 basic science research 0.557964 cancer genomic data 0.620842 Health Information Technology 0.575335 Pediatric MATCH trial 0.556198 information technology activities 0.552169 national cancer knowledge 0.623766 Genomics Application Programming 0.551737 precision medicine trial 0.626418 patient-derived tumor xenografts 0.568278 NCI-sponsored clinical trials 0.575743 Cancer Genomics Cloud 0.600078 deep immunological characterizations 0.554067 Cancer Genome Atlas 0.587186 first-of-its-kind Molecular Analysis 0.56172 canine immunotherapy models 0.585673 cancer 0.698472 Precision Medicine Initiative® 0.646721	CLICK HERE
3518	National Cancer Institute	Html	en	Use of Placebos	Information about placebos and their role in cancer clinical trials.	new treatment 0.545554 study 0.364583 patients 0.362034 medicine 0.367624 way 0.414648 treatment group 0.529513 to. 0.361225	doctors 0.371883 treatment clinical trials 0.815475 bias 0.382394 Placebos 0.570523 standard treatment 0.968379 cancer 0.37398	CLICK HERE
3676	National Cancer Institute	Html	en	Genomic Data Access	Information for NIH staff and extramural investigators on how to get a dbGaP account and how to request controlled-access data.	Supplementary Instructions 0.508326 trainees 0.351501 data use limitations 0.53645 access request form 0.751577 permanent employees 0.518968 cancer genotype-phenotype studies 0.653287 dbgap datasets 0.7932 Laboratory staff 0.513494 dbGaP Project Request 0.758272 Minimum Qualifications 0.520392 institution 0.370914 staff member 0.507438 database 0.339571 oversight 0.341561 responsibilities 0.337646 Extramural investigators 0.646629 postdoctoral fellows 0.532793 eRA Commons 0.541518 Applicants 0.337875 laboratory administration 0.514783 data access request 0.968754 NIH staff 0.519235 PIs 0.358599	tenure-track professor 0.518153 NCI Data Access 0.741329 signature approvals 0.518117 Eligibility requirements 0.511168 results 0.339375 email 0.333649 dbGaP Authorized Access 0.761069 seniorscientist 0.335515 Access Individual-Level Data 0.77002 principal investigators 0.705009 genotypes 0.422884 pre-existing account 0.549785 data access requests 0.732725 dbGaP Request Procedures 0.709981 graduate students 0.515113 phenotypes 0.420428 DAR 0.341157 access permission form 0.755217 project requests 0.50912 Investigators Requesting Authorized 0.770653 interaction 0.333238 access form 0.569266 online 0.337555	CLICK HERE
16822	National Cancer Institute	Html	es	Essiac y Flor Essence (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos sobre el uso de Essiac o Flor Essence como tratamiento para personas con cáncer. Nota: La información contenida en este sumario ya no se actualiza y se ofrece solo con fines de consulta.	Centro Nacional 0.301601 New Hampshire Avenue 0.301144 Drug Administration 0.30071 Flor Essence 0.987323 NCI Best Case 0.302063 modelos animales 0.300855 Indiana University-Purdue University 0.301652 datos bibliográficos pubmed 0.301216 siguientes preguntas 0.300694 productos essiac 0.309556 modelo animal 0.300781 PDQ Essiac 0.318217 National Cancer Institute 0.301364 Royal Cancer Commission 0.301752 Olmo resbaladizo 0.301149 siguientes riesgos 0.300858 Instituto Nacional 0.309533 Salud Complementaria 0.302607	Visuals Online 0.300813 complementarias revisa 0.30115 Physician Data Query 0.304689 Sloan Kettering Cancer 0.301678 Estados Unidos 0.332086 siguientes estudios 0.301314 libre uso 0.301062 distintos resultados 0.300776 únicos efectos 0.301309 ratón p388 0.301025 página manejo 0.300756 ¿El tratamiento 0.301379 Nueva York 0.300871 ¿Los beneficios 0.30071 juntos cam 0.300681 Series Program 0.300695 medicina complementaria 0.332457	CLICK HERE